Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 182 | $100,108,792 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 116,512 | 64.9163 | 7,563,528 | D |
01 Sep 2023 16:05 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Sep 2023 | Sale | 139,716 | 41.7025 | 5,826,506 | D |
05 Dec 2023 19:29 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 01 Dec 2023 | Sale | 67,557 | 60.5019 | 4,087,327 | D |
05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 62,503 | 64.2573 | 4,016,274 | D |
09 Apr 2024 16:25 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Apr 2024 | Sale | 64,379 | 54.1165 | 3,483,966 | D |
06 Jun 2023 16:59 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 05 Jun 2023 | Sale | 30,506 | 89.8259 | 2,740,229 | D |
06 Jun 2023 16:59 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 05 Jun 2023 | Sale | 30,609 | 87.7886 | 2,687,121 | D |
11 Mar 2024 16:08 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Mar 2024 | Sale | 42,750 | 61.8754 | 2,645,173 | D |
05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 41,704 | 62.9631 | 2,625,813 | D |
05 Dec 2023 19:29 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 01 Dec 2023 | Sale | 42,443 | 61.3052 | 2,601,977 | D |
20 Apr 2023 16:51 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 18 Apr 2023 | Sale | 30,000 | 82.024 | 2,460,720 | D |
09 May 2024 17:15 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 May 2024 | Sale | 56,335 | 42.1504 | 2,374,543 | D |
12 Aug 2022 16:57 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 11 Aug 2022 | Sale | 30,000 | 65.63 | 1,968,900 | I |
23 Mar 2023 16:55 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 21 Mar 2023 | Sale | 30,000 | 62.7444 | 1,882,332 | D |
05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 28,868 | 62.213 | 1,795,965 | D |
11 Mar 2024 16:08 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Mar 2024 | Sale | 26,257 | 62.6896 | 1,646,041 | D |
05 Dec 2023 16:21 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 01 Dec 2023 | Sale | 24,000 | 61.135 | 1,467,240 | I |
21 Jun 2024 19:34 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 21 Jun 2024 | Sale | 35,305 | 39.22 | 1,384,662 | I |
21 Dec 2022 16:13 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 19 Dec 2022 | Sale | 24,449 | 52.0697 | 1,273,052 | D |
18 May 2023 17:10 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 16 May 2023 | Sale | 14,611 | 85.0089 | 1,242,065 | D |
21 Nov 2023 16:00 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 17 Oct 2023 | Sale | 24,000 | 49 | 1,176,000 | I |
09 May 2023 17:02 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 May 2023 | Sale | 12,000 | 92.39 | 1,108,680 | D |
09 Jun 2023 16:40 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Jun 2023 | Sale | 12,000 | 91.35 | 1,096,200 | D |
20 Mar 2024 17:18 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 19 Mar 2024 | Sale | 18,681 | 57.179 | 1,068,161 | I |
11 Jul 2023 17:37 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 10 Jul 2023 | Sale | 12,000 | 84.55 | 1,014,600 | D |
08 Sep 2022 16:38 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 08 Sep 2022 | Sale | 15,000 | 65 | 975,000 | I |
09 May 2024 17:15 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 May 2024 | Sale | 22,472 | 42.849 | 962,903 | D |
11 Apr 2023 16:20 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 10 Apr 2023 | Sale | 12,000 | 78.21 | 938,520 | D |
23 Jan 2024 19:28 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 22 Jan 2024 | Sale | 13,431 | 64.996 | 872,961 | D |
16 Aug 2022 17:04 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 15 Aug 2022 | Sale | 12,500 | 69 | 862,500 | D |
12 Aug 2022 17:01 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 11 Aug 2022 | Sale | 12,500 | 67 | 837,500 | D |
09 Aug 2022 17:22 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 08 Aug 2022 | Sale | 12,500 | 65 | 812,500 | D |
12 Sep 2022 16:52 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Sep 2022 | Sale | 12,000 | 63.98 | 767,760 | D |
06 Jul 2023 16:20 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 03 Jul 2023 | Sale | 8,510 | 89.98 | 765,730 | D |
10 Mar 2023 17:18 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Mar 2023 | Sale | 12,000 | 63.79 | 765,480 | D |
01 Dec 2023 16:11 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 30 Nov 2023 | Sale | 13,858 | 54.73 | 758,448 | D |
09 Aug 2022 17:18 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Aug 2022 | Sale | 12,000 | 62.5 | 750,000 | D |
11 Oct 2022 16:58 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 10 Oct 2022 | Sale | 12,000 | 57.5 | 690,000 | D |
18 May 2023 17:10 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 16 May 2023 | Sale | 7,528 | 87.0163 | 655,059 | D |
10 Feb 2023 17:00 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Feb 2023 | Sale | 12,000 | 54.45 | 653,400 | D |
06 Jun 2023 16:59 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 05 Jun 2023 | Sale | 7,064 | 88.3649 | 624,210 | D |
05 Dec 2023 19:40 | APLS | Apellis Pharmaceuticals Inc | SCHEIBLER LUKAS | Chief Research Officer | 01 Dec 2023 | Sale | 10,000 | 60 | 600,000 | D |
12 Jul 2022 16:04 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Jul 2022 | Sale | 12,000 | 47.95 | 575,400 | D |
12 Dec 2022 16:28 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Dec 2022 | Sale | 12,000 | 47.5 | 570,000 | D |
09 Nov 2023 16:18 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Nov 2023 | Sale | 12,000 | 47.27 | 567,240 | D |
19 Mar 2024 16:03 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 18 Mar 2024 | Sale | 9,913 | 56.9 | 564,050 | D |
10 Nov 2022 08:30 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Nov 2022 | Sale | 12,000 | 46.47 | 557,640 | D |
10 Jan 2023 20:07 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 09 Jan 2023 | Sale | 12,000 | 46.08 | 552,960 | D |
17 Jan 2024 16:32 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 16 Jan 2024 | Sale | 7,851 | 66.8086 | 524,514 | D |
11 Sep 2023 16:58 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Sep 2023 | Sale | 12,000 | 42.87 | 514,440 | D |
19 Sep 2023 17:03 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 18 Sep 2023 | Sale | 10,631 | 46.147 | 490,589 | D |
10 Oct 2023 16:26 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 09 Oct 2023 | Sale | 12,000 | 40.38 | 484,560 | D |
24 Jan 2024 16:03 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 23 Jan 2024 | Sale | 7,378 | 63.69 | 469,905 | D |
14 Mar 2024 16:17 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 13 Mar 2024 | Sale | 7,768 | 57.307 | 445,161 | D |
21 Nov 2023 16:36 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 17 Nov 2023 | Sale | 8,894 | 49.991 | 444,620 | D |
01 Sep 2023 16:05 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Sep 2023 | Sale | 10,284 | 42.44 | 436,453 | D |
02 Jun 2023 16:40 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 01 Jun 2023 | Sale | 5,000 | 86 | 430,000 | D |
04 May 2023 16:40 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 03 May 2023 | Sale | 5,000 | 82.71 | 413,550 | D |
19 Sep 2023 17:03 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 18 Sep 2023 | Sale | 9,719 | 42.2085 | 410,224 | D |
05 Apr 2023 16:52 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 03 Apr 2023 | Sale | 5,000 | 75 | 375,000 | D |
05 Apr 2023 16:50 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 03 Apr 2023 | Sale | 5,000 | 74.05 | 370,250 | D |
18 Aug 2022 16:02 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Senior Vice President | 17 Aug 2022 | Sale | 5,000 | 69.5 | 347,500 | D |
18 Jan 2024 16:55 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 17 Jan 2024 | Sale | 5,207 | 65.58 | 341,475 | D |
12 Aug 2022 16:58 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Senior Vice President | 11 Aug 2022 | Sale | 5,000 | 67 | 335,000 | D |
05 Oct 2022 17:12 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 03 Oct 2022 | Sale | 5,000 | 66.69 | 333,450 | D |
09 Aug 2022 17:16 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Senior Vice President | 08 Aug 2022 | Sale | 5,000 | 64.5 | 322,500 | D |
07 Mar 2023 16:53 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 03 Mar 2023 | Sale | 5,000 | 63.84 | 319,200 | D |
08 Aug 2022 16:02 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Senior Vice President | 04 Aug 2022 | Sale | 5,000 | 62 | 310,000 | D |
07 Sep 2022 16:37 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 06 Sep 2022 | Sale | 5,000 | 60.38 | 301,900 | D |
08 Aug 2022 16:02 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Senior Vice President | 04 Aug 2022 | Sale | 5,000 | 59.5 | 297,500 | D |
06 Jul 2023 16:16 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 03 Jul 2023 | Sale | 3,287 | 90.4165 | 297,199 | D |
07 Nov 2022 16:19 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 03 Nov 2022 | Sale | 5,000 | 58.54 | 292,700 | D |
06 Jul 2023 16:16 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 03 Jul 2023 | Sale | 3,192 | 89.4109 | 285,400 | D |
28 Jul 2022 16:03 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Senior Vice President | 27 Jul 2022 | Sale | 5,000 | 57 | 285,000 | D |
09 Aug 2023 16:08 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Aug 2023 | Sale | 12,000 | 23.66 | 283,920 | D |
17 Jan 2024 16:38 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 16 Jan 2024 | Sale | 4,240 | 66.8086 | 283,268 | D |
04 Aug 2022 18:40 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 03 Aug 2022 | Sale | 5,000 | 56.43 | 282,150 | D |
21 Jul 2022 16:31 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Senior Vice President | 19 Jul 2022 | Sale | 5,000 | 56.42 | 282,100 | D |
06 Feb 2023 17:35 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 03 Feb 2023 | Sale | 5,000 | 55.85 | 279,250 | D |
24 Jan 2024 16:06 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 23 Jan 2024 | Sale | 4,286 | 63.69 | 272,975 | D |
23 Jan 2024 18:17 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 22 Jan 2024 | Sale | 4,184 | 64.996 | 271,943 | D |
13 Feb 2024 16:49 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 12 Feb 2024 | Sale | 3,962 | 67.7669 | 268,492 | D |
09 Apr 2024 16:25 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Apr 2024 | Sale | 4,728 | 54.9152 | 259,639 | D |
18 May 2023 17:10 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 16 May 2023 | Sale | 3,007 | 85.9012 | 258,305 | D |
23 Jan 2024 18:03 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 22 Jan 2024 | Sale | 3,913 | 64.996 | 254,329 | D |
05 Jan 2023 20:00 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 03 Jan 2023 | Sale | 5,000 | 50.7 | 253,500 | D |
07 Dec 2022 08:30 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 05 Dec 2022 | Sale | 5,000 | 50.38 | 251,900 | D |
05 Mar 2024 16:04 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 01 Mar 2024 | Sale | 4,000 | 62.86 | 251,440 | D |
21 Nov 2023 17:36 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 21 Nov 2023 | Sale | 5,000 | 48.8 | 244,000 | D |
12 Jul 2022 17:55 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 11 Jul 2022 | Sale | 5,000 | 48.42 | 242,100 | D |
02 Apr 2024 16:06 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 01 Apr 2024 | Sale | 4,000 | 58.66 | 234,640 | D |
25 Jan 2023 16:14 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 23 Jan 2023 | Sale | 4,479 | 51.58 | 231,027 | D |
23 Jan 2024 18:13 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 22 Jan 2024 | Sale | 3,551 | 64.996 | 230,801 | D |
23 Jan 2024 18:15 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 22 Jan 2024 | Sale | 3,413 | 64.996 | 221,831 | D |
18 Jan 2024 16:54 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 17 Jan 2024 | Sale | 3,276 | 65.58 | 214,840 | D |
14 Mar 2024 16:17 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 13 Mar 2024 | Sale | 3,452 | 58.1335 | 200,677 | D |
21 Dec 2022 16:13 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 19 Dec 2022 | Sale | 3,751 | 51.9678 | 194,931 | D |
18 May 2023 17:10 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 16 May 2023 | Sale | 2,120 | 87.6739 | 185,869 | D |
31 Jan 2024 16:26 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 29 Jan 2024 | Sale | 2,843 | 64.1382 | 182,345 | D |
23 Jan 2024 18:11 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 22 Jan 2024 | Sale | 2,593 | 64.996 | 168,535 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)